Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140426 · ClinicalTrials.gov registry record · Phase 4
A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa
A Phase 4 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
NCT00140426 is a Phase 4 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 41 participants.
The verdict
NCT00140426, a Phase 4 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
Study Summary
The aim of this pilot study is to determine the safety and efficacy of risperidone for the treatment of anorexia nervosa. Hypothesis 1: Subjects on risperidone will show a more significant decrease in body image distortion and Eating Disorder Inventory -2 scores than subjects on placebo. Hypothesis 2: Subjects on risperidone will reach and maintain at or above 90% Ideal body weight sooner than controls.
Interventions
- DRUG Placebo
- DRUG Risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2004-08 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00140426
The ClinicalTrials.gov registry entry for NCT00140426 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00140426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00140426 about?
NCT00140426 is a clinical study titled "A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa". The aim of this pilot study is to determine the safety and efficacy of risperidone for the treatment of anorexia nervosa. Hypothesis 1: Subjects on risperidone will show a more significant decrease in body image distortion and Eating Disorder Inventory -2 scores than subjects on placebo. Hypothesi...
What is the current status of trial NCT00140426?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2004-08. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00140426?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG).
Who is sponsoring clinical trial NCT00140426?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.